MSCL | Jotup

Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on:

Monday, April 8, 2024

Health, Biotechnology, TSX, MSCL, Conference

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at and participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16th and 17th in Toronto.

Key Points:

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at and participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16th and 17th in Toronto.
Mr. Frank Gleeson, Co-founder and CEO of Satellos, will provide a corporate presentation on Tuesday, April 16, 2024, at 11:30 a.m.
ET and will participate in one-on-one meetings during the conference along with the management team of Satellos.
The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website and a replay will be available following the presentation.

Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights

Retrieved on:

Wednesday, March 27, 2024

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ended December 31, 2023.

Key Points:

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ended December 31, 2023.
Subsequent to the year end, on March 4, 2024, Satellos announced positive preclinical data presented at the Muscular Dystrophy Association Clinical and Scientific Conference.
Satellos also announced that SAT-3247 would be nominated as its lead development candidate with SAT-3153 becoming the backup development candidate.
Satellos’ audited financial statements for the year ended December 31, 2023, and the related management’s discussion and analysis (MD&A) will be available on SEDAR+ at www.sedarplus.ca .

Satellos to Present at Upcoming Virtual Investor Conferences in March and April

Retrieved on:

Thursday, March 14, 2024

Health, Stem Cells, Genetics, Clinical Trials, Research, Science, Biotechnology, OTCQB, TSX, MSCL, Lobster

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, cofounder and CEO of Satellos, will present at the following investor conferences:

Key Points:

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, cofounder and CEO of Satellos, will present at the following investor conferences:
Date: Wednesday, March 20 at 8:00 a.m.
ET
Date: Wednesday, April 3 at 11:30 a.m.
ET
The fireside chats will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website and a replay will be available following the presentation.

Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024

Retrieved on:

Tuesday, March 5, 2024

Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, TSX, OTCQB, SVB Securities, MSCL, Conference

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that members from Satellos’ management team will host investor meetings at the Leerink Partners Global Biopharma Conference 2024 being held from Monday, March 11 to Wednesday, March 13 in Miami, Florida.

Key Points:

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that members from Satellos’ management team will host investor meetings at the Leerink Partners Global Biopharma Conference 2024 being held from Monday, March 11 to Wednesday, March 13 in Miami, Florida.
Institutional investors interested in meeting with members of Satellos’s senior management team during the conference may contact their representative at Leerink Partners for further information.

Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference

Retrieved on:

Monday, March 4, 2024

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration.

Key Points:

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration.
In all instances, treatment with SAT-3247 over a three-to-four-week period resulted in a statistically significant improvement in muscle force versus animals receiving placebo.
We believe the muscle injury data further expand and broaden the potential for SAT-3247 into non-dystrophy disease indications as well as multiple forms of muscle injury or trauma in otherwise healthy individuals.
We continue on our development plan to advance SAT-3247 into first-in-human clinical trials mid-year.”
These data are being presented in a poster at the 2024 MDA Clinical & Scientific Conference being held March 3-6 in Orlando.

Satellos Recognized as a Top 50 TSX Venture Exchange Company

Retrieved on:

Wednesday, February 21, 2024

Biotechnology, Pharmaceutical, Health, TSX, Exchange, Duchenne muscular dystrophy, MSCL, TSX Venture Exchange, TSX Venture 50

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has been named as one of the top performers on the TSX Venture Exchange.

Key Points:

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has been named as one of the top performers on the TSX Venture Exchange.
The 2024 TSX Venture 50 celebrates the strongest performance on the TSX Venture Exchange (the “TSXV” or “the Exchange”) over the last year.
“We are honored that Satellos has been recognized as a Top 50 company within the TSX Venture Exchange,” said Frank Gleeson, Co-founder and CEO of Satellos.
We look forward to a number of key milestones in 2024 including a Phase I clinical trial with SAT-3247.”
More details on the 2023 TSX Venture 50 and a video highlighting Satellos can be found at: www.tsx.com/Venture50 .

Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Retrieved on:

Tuesday, February 20, 2024

Health, Stem Cells, Genetics, Clinical Trials, Research, Science, Biotechnology, Molecule, TSX, Poster, Muscular Dystrophy Association, Event, MSCL, MDA, Regeneration, Episcopal conference, Skeletal muscle, Conference, Pharmaceutical industry

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced a late-breaking oral presentation and a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6 in Orlando.

Key Points:

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced a late-breaking oral presentation and a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6 in Orlando.
Title: SAT-3247: An Oral Small Molecule Inhibitor Targeting AAK1, a Critical Effector of Skeletal Muscle Regeneration
Copies of the presentation and poster will be available after each session on the Events & Presentations page located at: https://ir.satellos.com/events-and-presentations/default.aspx .

Satellos to Commence Trading on the Toronto Stock Exchange

Retrieved on:

Wednesday, February 14, 2024

Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, TSX, Toronto Stock Exchange, Duchenne, CUSIP, Indian stock exchange, Duchenne muscular dystrophy, MSCL, Pharmaceutical industry

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that its common shares will commence trading on the Toronto Stock Exchange (“TSX”) as of the opening of trading tomorrow under the Company’s current trading symbol, “MSCL”.

Key Points:

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that its common shares will commence trading on the Toronto Stock Exchange (“TSX”) as of the opening of trading tomorrow under the Company’s current trading symbol, “MSCL”.
“We are excited to complete the uplist to the Toronto Stock Exchange, which will provide access to a broader set of institutional investors from around the world,” said Frank Gleeson, Co-founder and CEO of Satellos.
“This uplisting reflects the milestones we have achieved with our accomplished team at Satellos as we transition from a preclinical to a clinical-stage company.
We look forward to achieving a number of key milestones this year as we look to advance our lead small molecule drug candidate for Duchenne muscular dystrophy into clinical trials and explore the potential of our small molecule regenerative medicine approach in other degenerative muscle diseases.”
Shareholders are not required to exchange their share certificates or direct registration system advices, or take any other action in connection with the listing on the TSX, as there will be no change in the trading symbol or CUSIP for the Common Shares.

Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy

Retrieved on:

Tuesday, February 13, 2024

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preliminary data showing SAT-3247 can improve skeletal muscle function in a mouse model of facioscapulohumeral muscular dystrophy (FSHD).

Key Points:

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preliminary data showing SAT-3247 can improve skeletal muscle function in a mouse model of facioscapulohumeral muscular dystrophy (FSHD).
We look forward to presenting these data at the MDA Clinical and Scientific Conference 2024 and advancing SAT-3247 into clinical trials for Duchenne muscular dystrophy mid-year.”
Neil Camarta, Co-Founder and CEO of the FSHD Canada Foundation, said “I’m very pleased.
I’m looking forward to working with Satellos to accelerate the development of this promising drug candidate, because time is muscle!”
FSHD is the third most common muscular dystrophy behind Duchenne (& Beckers) and myotonic dystrophy.
FSHD is an adult onset muscular dystrophy that results in the progressive destruction of muscle tissue, owed to the erroneous expression of a gene product called DUX4.

Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Retrieved on:

Tuesday, January 16, 2024

Health, Stem Cells, Health Technology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, CUSIP, Duchenne, Toronto Stock Exchange, GMP, IND, TSX, TSX Venture Exchange, Indian stock exchange, MSCL, Duchenne muscular dystrophy, Pharmaceutical industry

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (the “TSXV”) and to list its common shares (the “Common Shares”) on the TSX.

Key Points:

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (the “TSXV”) and to list its common shares (the “Common Shares”) on the TSX.
We remain on target to initiate clinical trials mid-2024.”
Final approval of the listing is subject to the Company meeting certain customary conditions required by the TSX.
The Company will issue a press release once the TSX confirms the date when trading of the Common Shares is expected to commence on the TSX.
Upon completion of the final TSX listing requirements, the Common Shares will be delisted from the TSXV.